AnnJi Pharmaceutical Reveals Phase 2a Breakthrough of AJ201 for SBMA at WMS 2025 AnnJi Pharmaceutical highlighted Phase 2a results of AJ201 for spinal and bulbar muscular atrophy at WMS 2025, indicating a major step forward.

AnnJi Pharmaceutical Reveals Phase 2a Breakthrough of AJ201 for SBMA at WMS 2025 #Taiwan #Taipei #AJ201 #SBMABio #AnnJi